Harris Poll notes increase in pharma reputation among Americans who know about GLP-1 drugs

GLP-1 med­ica­tions are help­ing to boost the phar­ma in­dus­try’s rep­u­ta­tion in the US. That’s ac­cord­ing to a Har­ris Poll run re­cent­ly to gauge gen­er­al pub­lic sen­ti­ment about the in­dus­try, and it in­clud­ed spe­cif­ic ques­tions about the GLP-1 drug cat­e­go­ry on be­half of End­points News.

55% of peo­ple who are tak­ing a GLP-1 or know some­one who is say they have a pos­i­tive per­cep­tion of the phar­ma in­dus­try. The num­ber drops to 50% among peo­ple who were fa­mil­iar with GLP-1s (but not tak­ing them or know any­one who is) and dips even fur­ther to 40% among those who are un­fa­mil­iar with the glucagon-like pep­tides class. The sam­ple size was 2,016 adults in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.